Geneva Partners LLC Reduces Stock Position in Ryan Specialty Holdings, Inc. (NYSE:RYAN)

Geneva Partners LLC trimmed its stake in shares of Ryan Specialty Holdings, Inc. (NYSE:RYAN) by 2.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 37,165 shares of the company’s stock after selling 1,052 shares during the period. Ryan Specialty makes up 1.0% of Geneva Partners LLC’s investment portfolio, making the stock its 29th largest holding. Geneva Partners LLC’s holdings in Ryan Specialty were worth $2,385,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Jennison Associates LLC grew its stake in shares of Ryan Specialty by 60.2% during the 3rd quarter. Jennison Associates LLC now owns 1,025,063 shares of the company’s stock valued at $68,054,000 after purchasing an additional 385,366 shares during the period. JPMorgan Chase & Co. grew its position in Ryan Specialty by 107.5% during the third quarter. JPMorgan Chase & Co. now owns 459,464 shares of the company’s stock valued at $30,504,000 after buying an additional 238,064 shares during the period. Bar Harbor Wealth Management increased its holdings in Ryan Specialty by 5.9% during the fourth quarter. Bar Harbor Wealth Management now owns 168,871 shares of the company’s stock valued at $10,835,000 after buying an additional 9,482 shares during the last quarter. Barclays PLC raised its position in Ryan Specialty by 1.1% in the third quarter. Barclays PLC now owns 1,641,743 shares of the company’s stock worth $108,994,000 after acquiring an additional 17,267 shares during the period. Finally, Crossmark Global Holdings Inc. purchased a new position in shares of Ryan Specialty during the 3rd quarter worth $475,000. Institutional investors own 84.82% of the company’s stock.

Ryan Specialty Trading Up 0.5 %

NYSE RYAN opened at $68.81 on Thursday. Ryan Specialty Holdings, Inc. has a 52 week low of $42.34 and a 52 week high of $75.97. The company has a 50 day moving average price of $66.40 and a 200 day moving average price of $66.73. The company has a quick ratio of 1.01, a current ratio of 1.01 and a debt-to-equity ratio of 2.40. The firm has a market cap of $18.02 billion, a PE ratio of 89.37, a price-to-earnings-growth ratio of 1.16 and a beta of 0.72.

Insiders Place Their Bets

In other news, EVP Mark Stephen Katz sold 14,790 shares of the stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $71.39, for a total value of $1,055,858.10. Following the transaction, the executive vice president now directly owns 12,386 shares of the company’s stock, valued at approximately $884,236.54. This represents a 54.42 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Nicholas Dominic Cortezi sold 31,409 shares of the business’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $65.64, for a total value of $2,061,686.76. Following the completion of the transaction, the director now directly owns 2,697 shares of the company’s stock, valued at approximately $177,031.08. This trade represents a 92.09 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 338,296 shares of company stock valued at $22,463,709. 11.10% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on RYAN shares. Bank of America raised their target price on Ryan Specialty from $75.00 to $84.00 and gave the stock a “buy” rating in a report on Thursday, October 10th. Keefe, Bruyette & Woods reduced their price objective on shares of Ryan Specialty from $79.00 to $77.00 and set an “outperform” rating on the stock in a research report on Friday, January 10th. Barclays raised their price target on Ryan Specialty from $76.00 to $88.00 and gave the company an “overweight” rating in a report on Thursday, November 21st. Morgan Stanley started coverage on Ryan Specialty in a research report on Thursday, December 5th. They set an “overweight” rating and a $90.00 target price on the stock. Finally, The Goldman Sachs Group increased their price target on Ryan Specialty from $64.00 to $72.00 and gave the stock a “neutral” rating in a report on Wednesday, October 9th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $74.40.

About Ryan Specialty

Ryan Specialty Holdings, Inc operates as a service provider of specialty products and solutions for insurance brokers, agents, and carriers in the United States, Canada, the United Kingdom, Europe, and Singapore. It offers distribution, underwriting, product development, administration, and risk management services by acting as a wholesale broker and a managing underwriter.